Noopept: The Russian Nootropic With 1,000+ Patients Studied That the West Has Never Heard Of

The short version

Noopept is a synthetic dipeptide nootropic that has been available over-the-counter in Russia since 2006. It costs roughly $0.10 per dose.
Over 1,000 patients have been studied across at least 16 clinical trials — but almost none of this research has been translated into English.
In the largest trial (360 patients across 12 Russian medical centers), Noopept significantly improved cognitive test scores over 2 months with minimal side effects.
It works at roughly 1/60th the dose of piracetam (20 mg vs. 1,200 mg) and, in head-to-head trials, showed faster onset and fewer adverse events.
Noopept has three distinct activity profiles: nootropic (memory and learning), neuroprotective (shields neurons from damage), and anxiolytic (reduces anxiety without sedation).
Its active metabolite, cycloprolylglycine, is identical to a naturally occurring neuropeptide in your brain.
The honest caveat: no double-blind, placebo-controlled trials exist. Most studies are open-label or use active comparators. Almost all clinical data comes from Russian institutions, with no independent Western replication.

Why people are curious about Noopept

Imagine you could take a pill that costs a dime, works in two weeks, and has been legally prescribed to hundreds of thousands of people — just not in your country.

That’s Noopept.

If you’ve spent any time in nootropic communities, you’ve probably seen it mentioned. It shows up on Reddit, in biohacking podcasts, and on supplement vendor sites, usually described as “1,000 times more potent than piracetam.” That claim gets thrown around a lot, and like most dramatic claims, it deserves a closer look.

Here’s what’s actually interesting about Noopept: it’s not some obscure research chemical with a single mouse study behind it. It’s a registered medicine in Russia, prescribed by neurologists, studied in over 1,000 patients across multiple clinical trials, and available without a prescription at any Russian pharmacy for about 400 rubles (roughly $4 for a month’s supply). It has been on the market since 2006. The Russian government re-registered it in 2024 with indefinite validity — meaning regulators reviewed the safety and efficacy data and said yes, keep selling it.

The problem? Almost none of this clinical data exists in English. Western nootropic communities are working with maybe 3-4 translated papers and a lot of speculation. The actual evidence base is far larger and far more interesting than what’s been available to English-speaking audiences.

This article is our attempt to fix that.

What Noopept actually is

Noopept (international nonproprietary name: omberacetam) is a synthetic dipeptide — a molecule made of two amino acids. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester, which you don’t need to remember. What matters is how it was designed and what it does.

It was created in 1992 at the V.V. Zakusov Research Institute of Pharmacology in Moscow by two scientists: Tatiana Gudasheva, a medicinal chemist, and Rita Ostrovskaya, a pharmacologist. Their approach was clever. They started with piracetam — the original nootropic, first synthesized in the 1960s — and noticed that its chemical structure contained two elements that looked like amino acid fragments. They asked a simple question: what if we built an actual dipeptide that mimicked those fragments?

They designed the simplest possible version first: a dipeptide of pyroglutamic acid and glycine. It worked — and it was 1,000 times more active than piracetam by weight. Through further optimization, they arrived at GVS-111, which they named Noopept (from “nootropic peptide”).

That “1,000 times more potent” number you see everywhere? It’s real, but it refers to the effective dose by weight, not the subjective experience. Piracetam is typically dosed at 1,200-4,800 mg per day. Noopept is dosed at 10-30 mg. It takes far less substance to produce a nootropic effect. That’s the comparison.

How it works in your brain

When you swallow a Noopept tablet, here’s what happens.

It absorbs fast. Oral bioavailability is 99.7%, which is remarkably high for a peptide. It reaches peak blood concentration in about 15 minutes. And here’s the interesting part: brain concentrations run approximately twice as high as blood concentrations. The drug preferentially accumulates in brain tissue.

It gets metabolized into something your brain already makes. Noopept’s primary active metabolite is cycloprolylglycine — a cyclic dipeptide. In 2002, Gudasheva’s team made a surprising discovery: cycloprolylglycine is not just a metabolite. It’s an endogenous neuropeptide that naturally occurs in your brain, derived from the processing of insulin-like growth factor I (IGF-I). In other words, Noopept is a prodrug for a molecule your brain already produces and uses.

It has three distinct effects:

Nootropic — Noopept improves all three phases of memory: initial processing, consolidation, and retrieval. This is different from piracetam, which primarily affects retrieval. In animal models, Noopept prevents amnesia caused by electroshock, cholinergic blockade, glutamatergic disruption, and REM sleep deprivation.
Neuroprotective — It shields neurons from damage caused by oxidative stress, excess calcium, and glutamate toxicity. One study found its antioxidant activity was two orders of magnitude (roughly 100x) more potent than vitamin E. It also reduces brain inflammation — anti-inflammatory effects comparable to diclofenac in one study.
Anxiolytic — It reduces anxiety without causing sedation, cognitive blunting, or dependence. The mechanism is distinct from benzodiazepines: rather than directly hitting GABA receptors, it activates inhibitory interneurons in the hippocampus, increasing inhibitory currents through a pathway involving alpha-7 nicotinic acetylcholine receptors.

It increases your brain’s own growth factors. Chronic Noopept use (28 days at 0.5 mg/kg/day in animal studies) increased NGF protein in the hypothalamus by 70%, BDNF protein in the hypothalamus by 60%, and BDNF mRNA in the hippocampus by 124% [Ostrovskaya et al., 2008, PMID: 19240853]. BDNF (brain-derived neurotrophic factor) is one of the most important molecules for learning, memory, and neuroplasticity.

What Russian doctors prescribe it for

Noopept is registered in Russia for the following conditions:

Memory disorders and attention deficits
Cognitive dysfunction and intellectual decline, including in elderly patients
Consequences of traumatic brain injury and postconcussion syndrome
Cerebrovascular insufficiency (reduced blood flow to the brain)
Asthenic disorders (chronic fatigue, mental exhaustion)
Emotional lability (mood instability, hyperexcitability)

The standard prescription is 20 mg per day (one 10 mg tablet in the morning, one in the afternoon), taken with food. Doctors can increase the dose to 30 mg per day if needed. The recommended course is 1.5 to 3 months, with at least a one-month break before repeating.

One important practical detail: the prescribing information says not to take it after 6:00 PM, since its mild stimulant properties can interfere with sleep.

Anxiolytic effects typically emerge at days 5-7. Cognitive improvements appear at days 14-20. Full effects are usually reached by the end of the first month.

The clinical evidence — what 16 studies actually show

This is where it gets interesting, and where this article differs from everything else you’ll find in English. We’ve tracked down 16 human clinical studies on Noopept. Here are the most significant.

The 360-patient multicenter trial

The largest Noopept study ever conducted was led by Academician N.N. Yakhno at the I.M. Sechenov Moscow Medical Academy and published in Lechaschi Vrach (Attending Physician) in 2009.

360 patients across 12 Russian medical centers (Moscow, St. Petersburg, Rostov-on-Don, Samara, Yekaterinburg, Novosibirsk, Kazan, Irkutsk)
Ages 50-80 (mean age 69.8), with stage I-II dyscirculatory encephalopathy (chronic cerebrovascular disease with cognitive impairment)
20 mg/day for 2 months
Results: MMSE scores improved from 26.36 to 28.14 (p<0.05). Clock Drawing Test improved from 7.90 to 9.35. Significant improvement in categorical verbal associations.
Only 14 adverse events reported across 360 patients (3.9%): 4 sleep disturbances, 4 headache exacerbations, 2 dizziness, 2 blood pressure elevation, 1 allergic reaction. 13 of 14 were mild.

Noopept vs. piracetam — the head-to-head trial

The most methodologically rigorous study was a Phase III randomized comparative trial by Neznamov and Teleshova, published in Korsakov’s Journal of Neurology and Psychiatry in 2008. This is the only Noopept clinical study with a partial English translation available [PMID: 19234797].

53 patients with mild cognitive disorders from vascular or traumatic brain disease
Noopept 20 mg/day vs. piracetam 1,200 mg/day for 56 days
Results: Noopept produced more pronounced cognitive improvements than piracetam, with benefits emerging earlier (day 7 vs. day 14). EEG showed increased alpha and beta rhythm power with decreased delta rhythm — a characteristic nootropic pattern.
Adverse events were 2.5 times less frequent in the Noopept group despite having 1.5 times more patients.

Post-stroke cognitive recovery

Amelin et al. (2011) studied 60 patients aged 50-80 who had suffered an ischemic stroke within the past year [PMID: 22500312].

30 received Noopept 20 mg/day, 30 served as controls
After 2 months: significant MMSE improvement vs. controls, significant improvement on categorical association tests (p<0.01)
100% treatment adherence. No significant adverse events.

The Alzheimer’s risk study — ApoE4 patients responded better

This may be the most provocative finding. Gavrilova et al. (2008) studied 20 elderly patients with amnestic-type mild cognitive impairment — the pattern most likely to progress to Alzheimer’s disease.

9 of 20 patients (45%) carried the ApoE4 genotype, which significantly increases Alzheimer’s risk
Noopept 20-30 mg/day for 3 months as monotherapy
70% showed positive therapeutic effect by end of month 1
Significant gains on Frontal Assessment Battery, Boston Naming Test, and Mattis Dementia Rating Scale
The critical finding: ApoE4-positive patients showed MORE pronounced clinical effects than ApoE4-negative patients.

This is counterintuitive and potentially important. The highest-risk patients responded best. This study is small (n=20) and needs replication, but it aligns with Noopept’s preclinical Alzheimer’s data, which shows effects on beta-amyloid pathology, tau hyperphosphorylation, and neurotrophic factor restoration — all processes that are disrupted in ApoE4 carriers.

The 2024 cardiovascular cognition study

The most recent Noopept clinical study was published in 2024 by Shishkova et al. in Nervous Diseases [DOI: 10.24412/2226-0757-2024-13193]. This is the first study to focus on working-age patients with cardiovascular comorbidities.

60 patients aged 18-65 with cognitive impairment plus hypertension, coronary artery disease, heart failure, and/or type 2 diabetes
30 received Noopept 20 mg/day + standard cardiovascular therapy. 30 received standard therapy only.
After 56 days:
- MoCA scores: Noopept group improved to 26 points vs. unchanged at 24 in control (p<0.001)
- Schulte table work efficiency improved by more than 10 seconds in the Noopept group — 6 times greater improvement than control
- Anxiety scores dropped significantly (p=0.001); depression scores dropped significantly (p=0.006)
- On the CGI clinician rating: 66.7% of Noopept patients achieved significant or marked improvement vs. 0% in control
Zero adverse events. No negative effects on blood pressure despite a population of cardiovascular patients.

Additional studies

Other clinical trials have shown benefits in:

Neurasthenia (n=40, ages 18-45): 65% clinical improvement, 70% reduction in tension headache intensity, zero adverse effects [Chutko et al., 2008, PMID: 19253467]
Young adults with vascular cognitive decline (n=85, ages 16-45): 44-52% symptom reduction at 1-year follow-up [Dolgova & Starodubtsev, 2010, PMID: 21510448]
Young adults with arterial hypotension (n=68, ages 18-45): Near-complete symptom resolution at 2-year follow-up — the longest human outcome data for Noopept
Post-TBI (n=30, ages 19-66): MMSE improved from 26.5 to 27.7 over 60 days, with improved attention on Schulte tables
Tuberculosis patients on chemotherapy (n=60): Noopept reduced the frequency of neuro- and cardiotoxic reactions to anti-TB drugs [Mordyk et al., 2009, PMID: 19565831]
Glaucoma with cardiovascular disease (n=20): Improved visual acuity and dark adaptation over 90 days

The preclinical Alzheimer’s connection

Beyond the clinical trials, Noopept has been tested across multiple Alzheimer’s disease models in animals — including a full doctoral dissertation by Anna Tsaplina (2009) conducted under Ostrovskaya’s supervision.

The findings across these models:

Beta-amyloid injection model: Noopept restored memory after amyloid injection into the Meynert basal nuclei, effective in both preventive and therapeutic modes [PMID: 19145356]
Olfactory bulbectomy model: Restored spatial memory AND stimulated antibody production against beta-amyloid — a dual mechanism combining cognitive improvement with immune-mediated amyloid clearance [Bobkova et al., PMID: 16277202]
Streptozotocin model (sporadic AD): Prevented cognitive decline, suppressed oxidative stress, enhanced BDNF and NGF selectively in the hippocampus [PMID: 20184279]
AD cellular model: Attenuated apoptosis, tau hyperphosphorylation, and calcium overload — three of the core pathological processes in Alzheimer’s [PMID: 25096780]
Alpha-synuclein (Parkinson’s): Modulated toxic oligomer formation, rescuing neuroblastoma cell viability [PMID: 21986202]. A 2022 study in PINK1-knockout rats showed intranasal Noopept reversed motor symptoms and restored midbrain dopamine neurons [PMID: 36614135].

None of this proves Noopept treats Alzheimer’s in humans. But the consistency of the preclinical data across multiple models, combined with the ApoE4 clinical finding, makes it one of the more interesting nootropic candidates for neurodegenerative research.

Safety — what we know and what we don’t

What we know:

The safety profile across clinical trials is remarkably clean. Across all studies, the most commonly reported side effects are mild and infrequent:

Blood pressure elevation in patients with pre-existing severe hypertension
Occasional sleep disturbance (which is why the prescribing information says not to take it after 6 PM)
Rare allergic reactions

In the 6-month chronic toxicity study in rabbits (10 and 100 mg/kg — doses far exceeding human use), there were no irreversible pathological changes in any organ system, no mutagenic activity, no immunotoxic effects, and no impact on reproductive function [Kovalenko et al., 2002, PMID: 12025790].

The LD50 is over 2,000 mg/kg orally in rats — roughly 100 times the human therapeutic dose. The safety ratio (ED50 to optimal dose) is approximately 10,000, compared to about 30 for piracetam.

The official prescribing information states: “Does not cause drug dependence or withdrawal syndrome.” No accumulation has been observed. No drug interactions have been documented with alcohol, sedatives, antihypertensives, or psychostimulants.

What we don’t know:

No formal post-marketing surveillance has been published despite 20 years on the Russian market
No Western-standard Phase IV study exists
The longest controlled clinical study lasted only 56 days (the 2-year follow-up was for a secondary condition)
Long-term cognitive outcomes beyond 3 months have not been systematically tracked
No studies in pregnant or breastfeeding women (contraindicated in the prescribing information)
No studies in patients under 18 (also contraindicated)

The honest limitations

We believe in being upfront about what the evidence doesn’t show. Here are the real limitations of the Noopept evidence base:

No double-blind, placebo-controlled RCTs. The most rigorous study (Neznamov & Teleshova) used piracetam as an active comparator, not placebo. Most other studies are open-label. By Western pharmaceutical standards, this is a significant gap.

No independent replication outside Russia. Virtually all clinical data comes from Russian institutions, many of which have historical connections to the drug’s developers. This doesn’t mean the data is fraudulent — but independent replication is how science builds confidence, and it hasn’t happened here.

Small sample sizes. Aside from the 360-patient multicenter trial, most studies enrolled 20-60 patients. These are hypothesis-generating, not definitive.

Potential conflicts of interest. Several studies were conducted by researchers affiliated with the Zakusov Institute where Noopept was developed, or were supported by the manufacturer (Otisifarm/Farmstandart).

Regulatory gap. Noopept is not FDA-approved. It is not approved in the EU, UK, or Australia. The FDA has issued import alerts for omberacetam. It exists in a regulatory gray area in the West — not illegal to possess in most jurisdictions, but not approved for any medical use.

The Russian approval is not equivalent to FDA approval. Russian drug registration involves clinical trial review, but the standards and process differ from the FDA’s requirements. Russian approval is meaningful context, not a substitute for the level of evidence Western regulators require.

What this means for you

If you’re considering Noopept, here’s the practical takeaway:

The evidence is more substantial than most nootropic communities realize. Over 1,000 patients across 16 clinical trials, a 20-year track record in Russian clinical practice, and a well-characterized mechanism of action — this is not a mystery compound with a single mouse study.
But it is also less proven than the marketing suggests. No placebo-controlled RCTs, no Western regulatory approval, no independent replication. “Better than most nootropics” is a low bar.
The approved dose is 20 mg/day (10 mg morning, 10 mg afternoon), with courses of 1.5-3 months. This is what was studied in clinical trials. Doses higher than 30 mg/day have not been clinically validated.
Consult a healthcare professional. This is not optional advice. If you have cardiovascular disease, a history of stroke or TBI, or are taking other medications, a physician’s guidance is essential.
Quality matters. If you’re sourcing Noopept outside of Russian pharmacies, the product may not match what was used in clinical trials. Third-party testing is advisable.

What’s next

Noopept sits in an unusual position. It has more clinical evidence than the vast majority of compounds discussed in nootropic communities — but less than what’s needed for Western regulatory approval. The preclinical Alzheimer’s data is genuinely compelling, and the ApoE4 finding could be significant if replicated in a larger trial.

What the field needs is straightforward: a well-designed, adequately powered, double-blind, placebo-controlled trial conducted at Western institutions with independent funding. Until that happens, Noopept will remain in the gap between “promising” and “proven” — a gap that is much narrower than most people realize, but still real.

Sources

Ostrovskaya R.U., Gudasheva T.A. Dipeptide drug Noopept: design, pharmacological properties and mechanism of action. Eksperimental’naia i Klinicheskaia Farmakologiia, 84(2), 2021. DOI: 10.30906/0869-2092-2021-84-2-41-52
Neznamov G.G., Teleshova E.S. Comparative study of Noopept and piracetam in patients with mild cognitive disorders. Neuroscience and Behavioral Physiology, 39(3), 2009. PMID: 19234797
Yakhno N.N., Damulin I.V., Antonenko L.M. Noopept in the treatment of dyscirculatory encephalopathy with moderate cognitive impairment. Lechaschi Vrach, 5, 2009, pp. 70-74.
Gavrilova S.I. et al. Clinical experience with Noopept for MCI syndrome. Modern Therapy of Mental Disorders, 31(1), 2008, pp. 27-32.
Shishkova V.N. et al. Assessment of Noopept treatment efficacy in patients with cognitive impairments associated with cardiovascular diseases. Nervous Diseases, 4, 2024. DOI: 10.24412/2226-0757-2024-13193
Amelin A.V., Ilyukhina A.Yu., Shmonin A.A. Noopept for moderate cognitive impairment in ischemic stroke patients. Korsakov’s Journal of Neurology and Psychiatry, 111(10), 2011, pp. 44-46. PMID: 22500312
Ostrovskaya R.U. et al. Noopept stimulates NGF and BDNF expression in rat hippocampus. Bulletin of Experimental Biology and Medicine, 146(3), 2008. PMID: 19240853
Kovalenko L.P. et al. Preclinical toxicology of Noopept. Eksperimental’naia i Klinicheskaia Farmakologiia, 65(1), 2002. PMID: 12025790
Kovalenko L.P. et al. Anti-inflammatory activity of Noopept. Eksperimental’naia i Klinicheskaia Farmakologiia, 65(2), 2002. PMID: 12109295
Kovalenko L.P. et al. Immunopharmacological properties of Noopept. Bulletin of Experimental Biology and Medicine, 143(6), 2007. PMID: 18256750
Ostrovskaya R.U. et al. Noopept restores memory in beta-amyloid model. Bulletin of Experimental Biology and Medicine, 146(4), 2008. PMID: 19145356
Bobkova N.V. et al. Noopept improves spatial memory and stimulates beta-amyloid antibodies. Eksperimental’naia i Klinicheskaia Farmakologiia, 2005. PMID: 16277202
Ostrovskaya R.U. et al. Noopept in streptozotocin sporadic Alzheimer’s model. 2010. PMID: 20184279
Ostrovskaya R.U. et al. Noopept attenuates apoptosis and tau hyperphosphorylation in AD cellular model. Journal of Biomedical Science, 21, 2014. PMID: 25096780
Jia X. et al. Noopept modulates alpha-synuclein oligomerization. Journal of Molecular Biology, 414(5), 2011. PMID: 21986202
Dagda R.K. et al. Intranasal Noopept reverses motor symptoms in PINK1-KO Parkinson’s model. Int J Mol Sci, 2022. PMID: 36614135
Zainullina L.F. et al. Noopept activates HIF-1 transcription factor. Doklady Biochemistry and Biophysics, 494, 2020. PMID: 33119829
Chutko L.S. et al. Noopept in neurasthenia. Korsakov’s Journal, 2008. PMID: 19253467
Dolgova I.N., Starodubtsev A.I. Noopept in young adults with vascular cognitive impairment. Korsakov’s Journal, 2010. PMID: 21510448
Mordyk A.V. et al. Noopept in tuberculosis chemotherapy. Klinicheskaia Meditsina, 2009. PMID: 19565831
Zimina I.A. et al. Injectable Noopept neuroprotective activity. Vestnik RUDN, Medicine, 4, 2004, pp. 192-196.
Avedisova A.S., Yastrebov D.V. Comparative efficacy of Noopept and piracetam for asthenic disorders. Russian Medical Journal, 15(5), 2007, pp. 434-437.
Pelsman A. et al. GVS-111 prevents oxidative damage in Down’s syndrome cortical neurons. Int J Dev Neurosci, 21(3), 2003. PMID: 12711349
Noopept official prescribing information. LP(004920)-(RG-RU), dated March 20, 2024. https://noopept.ru/files/noopept_instruction.pdf